Anzahl der Publikationen: 7
Zeitschriftenartikel
Gillessen, Sarah; Pluetschow, Annette; Vucinic, Vladan; Ostermann, Helmut; Kobe, Carsten; Broeckelmann, Paul J.; Boell, Boris; Eichenauer, Dennis A.; Heger, Jan-Michel; Borchmann, Sven; Fuchs, Michael; Borchmann, Peter; Engert, Andreas und Tresckow, Bastian von
(2022):
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
In: European Journal of Haematology, Bd. 109, Nr. 6: S. 728-735
Borchmann, Peter; Plutschow, Annette; Kobe, Carsten; Greil, Richard; Meissner, Julia; Topp, Max S.; Ostermann, Helmut; Dierlamm, Judith; Mohm, Johannes; Thiemer, Julia; Sokler, Martin; Kerkhoff, Andrea; Ahlborn, Miriam; Halbsguth, Teresa V.; Martin, Sonja; Keller, Ulrich; Balabanov, Stefan; Pabst, Thomas; Vogelhuber, Martin; Huttmann, Andreas; Wilhelm, Martin; Zijlstra, Josee M.; Moccia, Alden; Kuhnert, Georg; Brockelmann, Paul J.; Tresckow, Bastian von; Fuchs, Michael; Klimm, Beate; Rosenwald, Andreas; Eich, Hans; Baues, Christian; Marnitz, Simone; Hallek, Michael; Diehl, Volker; Dietlein, Markus und Engert, Andreas
(2021):
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trial.
In: Lancet Oncology, Bd. 22, Nr. 2: S. 223-234
Kreissl, Stefanie; Goergen, Helen; Buehnen, Ina; Kobe, Carsten; Moccia, Alden; Greil, Richard; Eichenauer, Dennis A.; Zijlstr, Josee M.; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Soekler, Martin; Beck, Hans Joachim; Willenbacher, Wolfgang; Ludwig, Wol-Dieter; Pabst, Thomas; Topp, Max S.; Hitz, Felicitas; Bentz, Martin; Keller, Ulrich Bernd; Kuehnhardt, Dagmar; Ostermann, Helmut; Hertenstein, Bernd; Ulitzky, Wafter A.; Maschmeyer, Georg; Vieler, Tons; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Diehl, Volker; Dietlein, Markus; Engert, Andreas und Borchmann, Peter
(2021):
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
In: Lancet Haematology, Bd. 8, Nr. 6, E398-E409
Broeckelmann, Paul J.; Goergen, Helen; Keller, Ulrich; Meissner, Julia; Ordemann, Rainer; Halbsguth, Teresa V.; Sasse, Stephanie; Soekler, Martin; Kerkhoff, Andrea; Mathas, Stephan; Huettmann, Andreas; Bormann, Matthias; Zimmermann, Andreas; Mettler, Jasmin; Fuchs, Michael; Tresckow, Bastian von; Baues, Christian; Rosenwald, Andreas; Klapper, Wolfram; Kobe, Carsten; Borchmann, Peter und Engert, Andreas
(2020):
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
In: Jama Oncology, Bd. 6, Nr. 6: S. 872-880
Borchmann, Peter; Goergen, Helen; Kobe, Carsten; Lohri, Andreas; Greil, Richard; Eichenauer, Dennis A.; Zijlstra, Josee M.; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Hüttmann, Andreas; Dierlamm, Judith; Sökler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst, Thomas; Topp, Max S.; Hitz, Felicitas; Bentz, Martin; Keller, Ulrich Bernd; Kuhnhardt, Dagmar; Ostermann, Helmut; Schmitz, Norbert; Hertenstein, Bernd; Aulitzky, Walter; Maschmeyer, Georg; Vieler, Tom; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Kuhnert, Georg; Diehl, Volker; Dietlein, Markus und Engert, Andreas
(2017):
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
In: Lancet, Bd. 390, Nr. 10114: S. 2790-2802
Borchmann, Peter; Haverkamp, Heinz; Lohri, Andreas; Mey, Ulrich; Kreissl, Stefanie; Greil, Richard; Markova, Jana; Feuring-Buske, Michaela; Meissner, Julia; Duehrsen, Ulrich; Ostermann, Helmut; Keller, Ulrich; Maschmeyer, Georg; Kuhnert, Georg; Dietlein, Markus; Kobe, Carsten; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Diehl, Volker und Engert, Andreas
(2017):
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
In: Lancet Oncology, Bd. 18, Nr. 4: S. 454-463
Eichenauer, Dennis A.; Plütschow, Annette; Kreissl, Stefanie; Sökler, Martin; Hellmuth, Johannes C.; Meissner, Julia; Mathas, Stephan; Topp, Max S.; Behringer, Karolin; Klapper, Wolfram; Kuhnert, Georg; Dietlein, Markus; Kobe, Carsten; Fuchs, Michael; Diehl, Volker; Engert, Andreas und Borchmann, Peter
(2017):
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
In: Lancet Oncology, Bd. 18, Nr. 12: S. 1680-1687
Diese Liste wurde am
Sat Dec 21 22:40:40 2024 CET
erstellt.